Re-admissions for delayed complications after cytoreductive surgery and HIPEC

References

• Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:e362–369.
   PubMed Web of Science ®Google Scholar
• Kulu Y, Müller-Stich B, Büchler MW, Ulrich A. Surgical treatment of peritoneal carcinomatosis: current treatment modalities. Langenbecks Arch Surg. 2014;399:41–53.
   PubMed Web of Science ®Google Scholar
• Spiliotis JD, Halkia EA, Efstathiou E. Peritoneal carcinomatosis 2011; it's about time for chemosurgery. J BUON. 2011;16:400–408.
   PubMed Web of Science ®Google Scholar
• Elias D, Goere D, Blot F, Billard V, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818–1824.
   PubMed Web of Science ®Google Scholar
• Ihemelandu CU, McQuellon R, Shen P, et al. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS + HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol. 2013;20:3519–3526.
   PubMed Web of Science ®Google Scholar
• Votanopoulos KI, Russell G, Randle RW, et al. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22:1274–1279.
   PubMed Web of Science ®Google Scholar
• Cripe J, Tseng J, Eskander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. Ann Surg Oncol. 2015;22:655–661.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23:431–442.
   PubMed Web of Science ®Google Scholar
• Halkia E, Kopanakis N, Nikolaou G, Spiliotis J. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. J BUON. 2015;20:S80–S87.
   PubMedGoogle Scholar
• Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res. 2007;134:247–264.
   PubMedGoogle Scholar
• Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–731.
   PubMed Web of Science ®Google Scholar
• Halkia E, Gavriel S, Spiliotis J. Management of peritoneal surface malignancy: a review of the recent literature. J BUON. 2014;19:618–626.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
   PubMed Web of Science ®Google Scholar
• Halkia E, Efstathiou E, Rogdakis A, et al. Digestive fistulas after cytoreductive surgery & HIPEC in peritoneal carcinomatosis. J BUON. 2015;20:S60–S63.
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–363.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Rogdakis A, et al. Clinical history of patients with peritoneal carcinomatosis exluded from cytoreductive surgery & HIPEC. J BUON. 2015;20:244–247.
   PubMed Web of Science ®Google Scholar
• Jafari MD, Halabi WJ, Stamos MJ, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2014;149:170–175.
   PubMed Web of Science ®Google Scholar
• Bhagwandin SB, Naffouje S, Salti G. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge. J Surg Oncol. 2015;111:324–327.
   PubMed Web of Science ®Google Scholar
• Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg. 2013;71:434–440.
   PubMed Web of Science ®Google Scholar
• Zovak M, Mužina Mišić D, Glavčić G. Pancreatic surgery: evolution and current tailored approach. Hepatobiliary Surg Nutr. 2014;3:247–258.
   PubMedGoogle Scholar
• Malina M. Reinterventions after open and endovascular AAA repair. J Cardiovasc Surg (Torino). 2015;56:257–268.
   PubMed Web of Science ®Google Scholar